Plain-English translation of NCT06026878 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new combination of three medications—gemcitabine, nimotuzumab, and toripalimab—works as well as or better than the current standard treatment (gemcitabine plus cisplatin) for people with advanced nasopharyngeal cancer. Both groups will receive two cycles of their assigned induction treatment, followed by standard chemoradiotherapy. The study wants to see if the new medication combination can achieve the same response rates with potentially fewer side effects.
Advanced nasopharyngeal cancer is difficult to treat, and the current standard chemotherapy can cause significant side effects. This trial explores whether this new treatment approach might be equally or more effective while potentially being easier for patients to tolerate.
You likely qualify if…
You likely don't qualify if…
If you're accepted into this study, you'll be randomly assigned to receive either the new three-drug combination or the standard two-drug chemotherapy. You'll receive two cycles of induction treatment over 6 weeks (medications given intravenously every 3 weeks), followed by standard chemoradiotherapy. You'll have regular blood tests and imaging scans to monitor how well the treatment is working and watch for side effects. The study involves visits to the hospital for infusions and follow-up care over several months.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
China